{"id":"https://openalex.org/W2585129131","doi":"https://doi.org/10.1182/blood.v128.22.1062.1062","title":"BET Bromodomain Degradation As a Therapeutic Strategy in Multiple Myeloma","display_name":"BET Bromodomain Degradation As a Therapeutic Strategy in Multiple Myeloma","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2585129131","doi":"https://doi.org/10.1182/blood.v128.22.1062.1062","mag":"2585129131"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.1062.1062","doi":"https://doi.org/10.1182/blood.v128.22.1062.1062","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.1062.1062","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023676277","display_name":"Geoffrey M. Matthews","orcid":"https://orcid.org/0000-0002-2804-2021","observed_orcids":["https://orcid.org/0000-0002-2804-2021"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey M. Matthews","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068511166","display_name":"Sara Gandolfi","orcid":"https://orcid.org/0000-0001-6207-4433","observed_orcids":["https://orcid.org/0000-0001-6207-4433"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I189158943","display_name":"University of Milan","ror":"https://ror.org/00wjc7c48","country_code":"IT","type":"education","lineage":["https://openalex.org/I189158943"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["IT","US"],"is_corresponding":false,"raw_author_name":"Sara Gandolfi","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","University of Milano and Humanitas Research Hospital, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"University of Milano and Humanitas Research Hospital, Milano, Italy","institution_ids":["https://openalex.org/I189158943"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068400739","display_name":"Johanna Bruggentheis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johanna Bruggentheis","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005661878","display_name":"Ricardo De Matos Simoes","orcid":"https://orcid.org/0000-0002-1700-5276","observed_orcids":["https://orcid.org/0000-0002-1700-5276"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ricardo De Matos Simoes","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075891845","display_name":"Dennis L. Buckley","orcid":"https://orcid.org/0000-0003-1916-7807","observed_orcids":["https://orcid.org/0000-0003-1916-7807"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis L Buckley","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039965800","display_name":"Yiguo Hu","orcid":"https://orcid.org/0000-0002-3973-2140","observed_orcids":["https://orcid.org/0000-0002-3973-2140"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiguo Hu","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023112790","display_name":"Michal Sheffer","orcid":"https://orcid.org/0000-0001-5934-9950","observed_orcids":["https://orcid.org/0000-0001-5934-9950"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michal Sheffer","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029298840","display_name":"Hayley Poarch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hayley Poarch","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110274677","display_name":"James E. Bradner","orcid":"https://orcid.org/0000-0002-2718-4415","observed_orcids":["https://orcid.org/0000-0002-2718-4415","https://orcid.org/0000-0003-1422-5318"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James E. Bradner","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute/ Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute/ Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine S Mitsiades","raw_affiliation_strings":["Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.1307,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.54575968,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"128","issue":"22","first_page":"1062","last_page":"1062"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.007799999788403511,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/jq1","display_name":"JQ1","score":0.9430000185966492},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8529999852180481},{"id":"https://openalex.org/keywords/crispr-cas9-screening","display_name":"CRISPR-Cas9 screen","score":0.8109999895095825},{"id":"https://openalex.org/keywords/mm-1s-cells","display_name":"MM.1S cells","score":0.7039999961853027},{"id":"https://openalex.org/keywords/bortezomib-resistance","display_name":"bortezomib resistance","score":0.7760000228881836},{"id":"https://openalex.org/keywords/lenalidomide-resistance","display_name":"lenalidomide resistance","score":0.8420000076293945},{"id":"https://openalex.org/keywords/stromal-cells","display_name":"stromal cells","score":0.5400000214576721}],"concepts":[{"id":"https://openalex.org/C74401373","wikidata":"https://www.wikidata.org/wiki/Q1829843","display_name":"Bromodomain","level":4,"score":0.8759287595748901},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6457135677337646},{"id":"https://openalex.org/C98108389","wikidata":"https://www.wikidata.org/wiki/Q412563","display_name":"CRISPR","level":3,"score":0.643420934677124},{"id":"https://openalex.org/C2779634854","wikidata":"https://www.wikidata.org/wiki/Q18037206","display_name":"BRD4","level":5,"score":0.6243767142295837},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6056963205337524},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5384812951087952},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.45239511132240295},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4395831227302551},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.43914830684661865},{"id":"https://openalex.org/C2780862049","wikidata":"https://www.wikidata.org/wiki/Q25326844","display_name":"BET inhibitor","level":5,"score":0.41245827078819275},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.22392866015434265},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.21728351712226868},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2153947651386261},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.19692134857177734}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.1062.1062","doi":"https://doi.org/10.1182/blood.v128.22.1062.1062","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.1062.1062","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2499149931","https://openalex.org/W2588726445","https://openalex.org/W2549779868","https://openalex.org/W2588683607","https://openalex.org/W4234381951","https://openalex.org/W2024764353","https://openalex.org/W2558951680","https://openalex.org/W2955921074","https://openalex.org/W4389219599","https://openalex.org/W2794265154"],"abstract_inverted_index":{"Abstract":[0],"Multiple":[1],"myeloma":[2],"(MM)":[3],"remains":[4,27],"an":[5,197,361],"incurable":[6],"malignancy":[7],"with":[8,105,145,218,226,273,316,357],"a":[9,28,69,151,282,376,427,559],"clear":[10],"need":[11],"for":[12,461,572],"novel":[13,25],"therapeutic":[14],"modalities.":[15],"Moreover,":[16],"acquired":[17],"or":[18,24,295,313,521],"de":[19],"novo":[20],"resistance":[21,117,219,333,527,543],"to":[22,86,97,118,128,133,164,184,220,256,264,291,303,324,327,334,339,425,441,497,548,562],"established":[23],"therapeutics":[26],"major":[29],"challenge":[30],"in":[31,46,49,50,63,90,108,150,364,379,430,448,494,565],"this,":[32,139],"and":[33,48,58,92,110,126,167,169,176,188,228,247,280,318,342,349,351,367,385,394,466,472,482,503,555],"other,":[34],"neoplasias.":[35],"BET":[36,77],"Bromodomain":[37],"inhibitors":[38],"(BBIs),":[39],"including":[40,161],"JQ1,":[41,165,312],"have":[42,87,304],"potent":[43,88],"anti-MM":[44],"activity":[45,89],"vitro":[47],"vivo,":[51],"but":[52],"do":[53,59],"not":[54,60,396],"provide":[55],"curative":[56],"outcome":[57],"induce":[61,340,397],"apoptosis":[62],"many":[64],"tumor":[65],"cell":[66,156],"types.":[67],"Recently,":[68],"\"next-generation\"":[70],"BBI,":[71],"dBET,":[72],"that":[73,116,319,484,515,537,545],"causes":[74],"degradation":[75,107,193,345,481,552],"of":[76,143,153,191,232,237,260,270,284,346,353,388,399,409,418,459,464,475,487,501,517,519,541,553],"Bromodomains":[78],"(BRDs)":[79],"through":[80,123],"CRBN-mediated":[81],"ubiquitination":[82],"has":[83],"been":[84],"demonstrated":[85],"leukemia":[91],"myeloma.":[93],"Here":[94],"we":[95,114,140,210,213,254],"sought":[96,255],"compare":[98,185],"the":[99,186,233,258,268,419,443,445,457,462,522],"mechanistic":[100],"differences":[101],"between":[102,278,477],"BRD":[103,106,192,478],"inhibition":[104,479],"treatment-naive":[109,465],"drug-resistant":[111,467],"MM.":[112,468],"Additionally,":[113,511],"posited":[115],"dBET":[119,274,449,460,490,526,542],"treatment":[120,463],"could":[121,214],"emerge":[122],"genetic":[124],"perturbations":[125],"wished":[127],"uncover":[129,215],"potential":[130],"mechanisms":[131,474,540],"prior":[132],"its":[134,314],"clinical":[135],"utilization.":[136],"To":[137],"address":[138],"compared":[141,356],"effects":[142,190],"JQ1":[144,329,358,390,488],"lead":[146],"optimized":[147],"compound":[148],"dBET6,":[149],"panel":[152],"human":[154],"MM":[155,261,309],"lines":[157],"(\u00b1":[158],"stromal":[159],"cells),":[160],"clones":[162],"resistant":[163,263,323],"bortezomib":[166,331],"IMIDs,":[168],"assessed":[170],"viability":[171],"using":[172,297,437],"CS-BLI/CTG":[173],"assay.":[174],"RNAseq":[175],"reverse":[177],"phase":[178],"protein":[179,366,382],"arrays":[180],"(RPPA)":[181],"were":[182,224,289,322],"employed":[183],"transcriptional":[187],"translational":[189],"vs.":[194,480,489],"inhibition.":[195],"Using":[196,250],"open-ended":[198],"unbiased":[199],"genome-wide":[200],"CRISPR":[201],"(clustered":[202],"regularly":[203],"interspaced":[204],"short":[205],"palindromic":[206],"repeats)-associated":[207],"Cas9":[208,227],"approach,":[209],"examined":[211],"whether":[212],"genes":[216,246],"associated":[217],"dBET6.":[221,265,325,335],"MM1.S":[222],"cells":[223,262,271,288,310,321,547],"transduced":[225],"pooled":[229,239],"lentiviral":[230],"particles":[231],"GeCKO":[234],"library,":[235],"consisting":[236],"2":[238],"sgRNA":[240,293],"sub-libraries":[241],"(~120,000":[242],"sgRNAs;":[243],"targeting":[244,411],"~19,000":[245],"~1800":[248],"miRNAs).":[249],"this":[251,556],"CRISPR/Cas9-based":[252],"approach":[253],"expedite":[257],"isolation":[259],"We":[266,300,336,469],"treated":[267],"pool":[269],"thrice":[272],"(250nM),":[275],"allowing":[276],"regrowth":[277],"treatments":[279],"maintaining":[281],"coverage":[283],"1000":[285],"cells/sgRNA.":[286],"dBET6-resistant":[287],"processed":[290],"quantify":[292],"enrichment":[294,408],"depletion,":[296],"deep":[298],"sequencing.":[299],"observed":[301,337],"dBET6":[302,338,374],"significantly":[305,368],"greater":[306,499],"potency":[307],"against":[308],"than":[311],"combination":[315],"lenalidomide,":[317],"MM1S.CRBN-/-":[320],"Resistance":[326],"neither":[328],"nor":[330],"conferred":[332],"rapid":[341],"robust":[343],"(<4hrs)":[344],"BRD2,":[347],"BRD3":[348],"BRD4":[350,365,531],"loss":[352,500,516],"c-MYC":[354,370,502],"protein,":[355],"which":[359],"caused":[360,375,391],"apparent":[362],"increase":[363],"less":[369],"down-regulation.":[371],"Interestingly,":[372],"while":[373],"time-dependent":[377],"reduction":[378],"pro-survival":[380],"Mcl-1":[381,392,504],"(among":[383],"others)":[384],"increased":[386],"cleavage":[387,398],"caspase-3/7,":[389],"upregulation":[393],"did":[395],"caspase-3/7.":[400],"As":[401],"predicted,":[402],"our":[403,453,512],"CRISPR/Cas9":[404],"screen":[405],"identified":[406],"significant":[407],"sgRNAs":[410,439],"CRBN,":[412],"as":[413,415],"well":[414],"several":[416],"members":[417],"Cullin-RING":[420],"ligase":[421,433],"(CRL)":[422],"complex,":[423],"known":[424],"play":[426],"critical":[428],"role":[429,444],"E3":[431],"ubiquitin":[432],"activity.":[434],"Preliminary":[435],"experiments":[436],"individual":[438],"appear":[440],"validate":[442],"CRL":[446,523],"complex":[447,524],"resistance.":[450],"In":[451],"summary,":[452],"data":[454],"strongly":[455],"support":[456],"development":[458],"demonstrate":[470,514],"overlapping":[471],"distinct":[473],"action":[476],"suggest":[483],"differential":[485],"potencies":[486],"is,":[491],"at":[492],"least":[493],"part,":[495],"due":[496],"far":[498],"expression,":[505],"however":[506],"further":[507],"analysis":[508],"is":[509,535],"warranted.":[510],"results":[513],"function":[518],"CRBN":[520],"induces":[525],"by":[528],"perturbing":[529],"dBET-mediated":[530],"degradation.":[532],"However,":[533],"it":[534],"plausible":[536],"additional":[538],"CRBN/CRL-independent":[539],"exist":[544],"allow":[546],"survive":[549],"despite":[550],"complete":[551],"BRDs":[554],"will":[557],"be":[558,563],"key":[560],"question":[561],"answered":[564],"future":[566],"studies.":[567],"Disclosures":[568],"Bradner:":[569],"Novartis":[570],"Institutes":[571],"BioMedical":[573],"Research:":[574],"Employment.":[575]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-02-10T00:00:00"}